Similar articles for PMID: 27104166

Year	Number of Results
2000	1
2001	1
2002	1
2003	1
2005	4
2007	5
2008	4
2009	3
2010	8
2011	5
2012	9
2013	6
2014	8
2015	8
2016	14
2017	9
2018	12
2019	14
2020	8
2021	12
2022	13
2023	1
2024	0

1

Hypofractionated intensity-modulated radiotherapy in patients with localized prostate cancer: a preliminary study.

Kang HJ, Kay CS, Son SH, Kim M, Jo IY, Lee SJ, Lee DH, Suh HJ, Choi YS. Kang HJ, et al. Radiat Oncol J. 2016 Mar;34(1):45-51. doi: 10.3857/roj.2016.34.1.45. Epub 2016 Mar 30. Radiat Oncol J. 2016. PMID: 27104166 Free PMC article.

2

Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.

Zilli T, Jorcano S, Escudé L, Linero D, Rouzaud M, Dubouloz A, Miralbell R. Zilli T, et al. Clin Oncol (R Coll Radiol). 2014 Jun;26(6):316-22. doi: 10.1016/j.clon.2014.02.014. Epub 2014 Mar 22. Clin Oncol (R Coll Radiol). 2014. PMID: 24667210

3

Safety of accelerated hypofractionated whole pelvis radiation therapy prior to high dose rate brachytherapy or stereotactic body radiation therapy prostate boost.

Phuong C, Chan JW, Ni L, Wall P, Mohamad O, Wong AC, Hsu IC, Chang AJ. Phuong C, et al. Radiat Oncol. 2022 Jan 20;17(1):12. doi: 10.1186/s13014-021-01976-2. Radiat Oncol. 2022. PMID: 35057827 Free PMC article.

4

Phase 1/2 study of hypofractionated intensity-modulated radiation therapy for prostate cancer including simultaneously integrated boost.

Chang MG, Mukhopadhyay N, Holdford D, Skinner V, Saraiya S, Moghanaki D, Anscher MS. Chang MG, et al. Pract Radiat Oncol. 2018 May-Jun;8(3):e149-e157. doi: 10.1016/j.prro.2017.09.007. Epub 2017 Sep 18. Pract Radiat Oncol. 2018. PMID: 29290572 Clinical Trial.

5

Twice-weekly hypofractionated intensity-modulated radiotherapy for localized prostate cancer with low-risk nodal involvement: toxicity and outcome from a dose escalation pilot study.

Zilli T, Jorcano S, Rouzaud M, Dipasquale G, Nouet P, Toscas JI, Casanova N, Wang H, Escudé L, Mollà M, Linero D, Weber DC, Miralbell R. Zilli T, et al. Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):382-9. doi: 10.1016/j.ijrobp.2010.05.057. Epub 2010 Sep 29. Int J Radiat Oncol Biol Phys. 2011. PMID: 20884129

6

Late toxicity and quality of life with prostate only or whole pelvic radiation therapy in high risk prostate cancer (POP-RT): A randomised trial.

Murthy V, Maitre P, Bhatia J, Kannan S, Krishnatry R, Prakash G, Bakshi G, Pal M, Menon S, Mahantshetty U. Murthy V, et al. Radiother Oncol. 2020 Apr;145:71-80. doi: 10.1016/j.radonc.2019.12.006. Epub 2020 Jan 7. Radiother Oncol. 2020. PMID: 31923712 Clinical Trial.

7

Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.

Deville C, Both S, Hwang WT, Tochner Z, Vapiwala N. Deville C, et al. Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):763-72. doi: 10.1016/j.ijrobp.2009.08.043. Epub 2010 Feb 18. Int J Radiat Oncol Biol Phys. 2010. PMID: 20171807

8

Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.

Akimoto T, Ito K, Saitoh J, Noda SE, Harashima K, Sakurai H, Nakayama Y, Yamamoto T, Suzuki K, Nakano T, Niibe H. Akimoto T, et al. Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):463-71. doi: 10.1016/j.ijrobp.2004.11.041. Int J Radiat Oncol Biol Phys. 2005. PMID: 16168838

9

Ten-Year Outcomes of Moderately Hypofractionated (70 Gy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer.

Abu-Gheida I, Reddy CA, Kotecha R, Weller MA, Shah C, Kupelian PA, Mian O, Ciezki JP, Stephans KL, Tendulkar RD. Abu-Gheida I, et al. Int J Radiat Oncol Biol Phys. 2019 Jun 1;104(2):325-333. doi: 10.1016/j.ijrobp.2019.01.091. Epub 2019 Feb 2. Int J Radiat Oncol Biol Phys. 2019. PMID: 30721720

10

A Phase II trial of arc-based hypofractionated intensity-modulated radiotherapy in localized prostate cancer.

Lock M, Best L, Wong E, Bauman G, D'Souza D, Venkatesan V, Sexton T, Ahmad B, Izawa J, Rodrigues G. Lock M, et al. Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1306-15. doi: 10.1016/j.ijrobp.2010.04.054. Epub 2010 Aug 12. Int J Radiat Oncol Biol Phys. 2011. PMID: 20708855 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

127 results

Results by year